FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980937306> ?p ?o ?g. }

• W2980937306 endingPage "798" @default.
• W2980937306 startingPage "787" @default.
• W2980937306 abstract "RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5-0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1-66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%; HR [95% CI]: 0.146 [0.098-0.218]; OS estimates at 5 years: 83% vs 68%; HR [95% CI]: 0.450 [0.266-0.761]). Ibrutinib benefit was also consistent in patients with high prognostic risk (TP53 mutation, 11q deletion, and/or unmutated IGHV) (PFS: HR [95% CI]: 0.083 [0.047-0.145]; OS: HR [95% CI]: 0.366 [0.181-0.736]). Investigator-assessed overall response rate was 92% with ibrutinib (complete response, 30%; 11% at primary analysis). Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time. Fifty-eight percent of patients continue to receive ibrutinib. Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time." @default.
• W2980937306 created "2019-10-25" @default.
• W2980937306 creator A5007254355 @default.
• W2980937306 creator A5008054206 @default.
• W2980937306 creator A5008204241 @default.
• W2980937306 creator A5036828560 @default.
• W2980937306 creator A5038243788 @default.
• W2980937306 creator A5047631289 @default.
• W2980937306 creator A5054416214 @default.
• W2980937306 creator A5055100327 @default.
• W2980937306 creator A5056554686 @default.
• W2980937306 creator A5058755419 @default.
• W2980937306 creator A5059360959 @default.
• W2980937306 creator A5059772145 @default.
• W2980937306 creator A5062041233 @default.
• W2980937306 creator A5062322697 @default.
• W2980937306 creator A5081151755 @default.
• W2980937306 creator A5083822738 @default.
• W2980937306 creator A5087571749 @default.
• W2980937306 creator A5089625305 @default.
• W2980937306 creator A5090615083 @default.
• W2980937306 date "2019-10-18" @default.
• W2980937306 modified "2023-10-15" @default.
• W2980937306 title "Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study" @default.
• W2980937306 cites W1829587101 @default.
• W2980937306 cites W1986924929 @default.
• W2980937306 cites W2031191067 @default.
• W2980937306 cites W2047982141 @default.
• W2980937306 cites W2070487917 @default.
• W2980937306 cites W2098428600 @default.
• W2980937306 cites W2108206643 @default.
• W2980937306 cites W2120319857 @default.
• W2980937306 cites W2142099365 @default.
• W2980937306 cites W2233614027 @default.
• W2980937306 cites W2295348655 @default.
• W2980937306 cites W2316021978 @default.
• W2980937306 cites W2396328865 @default.
• W2980937306 cites W2493501265 @default.
• W2980937306 cites W2580500393 @default.
• W2980937306 cites W2587059675 @default.
• W2980937306 cites W2605172177 @default.
• W2980937306 cites W2606995900 @default.
• W2980937306 cites W2623762297 @default.
• W2980937306 cites W2739393823 @default.
• W2980937306 cites W2747656856 @default.
• W2980937306 cites W2769684200 @default.
• W2980937306 cites W2787863642 @default.
• W2980937306 cites W2787916641 @default.
• W2980937306 cites W2804951327 @default.
• W2980937306 cites W2806627663 @default.
• W2980937306 cites W2888047356 @default.
• W2980937306 cites W2888496958 @default.
• W2980937306 cites W2896564439 @default.
• W2980937306 cites W2897636215 @default.
• W2980937306 cites W2900467419 @default.
• W2980937306 cites W2902484351 @default.
• W2980937306 cites W2902706178 @default.
• W2980937306 doi "https://doi.org/10.1038/s41375-019-0602-x" @default.
• W2980937306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7214263" @default.
• W2980937306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31628428" @default.
• W2980937306 hasPublicationYear "2019" @default.
• W2980937306 type Work @default.
• W2980937306 sameAs 2980937306 @default.
• W2980937306 citedByCount "298" @default.
• W2980937306 countsByYear W29809373062019 @default.
• W2980937306 countsByYear W29809373062020 @default.
• W2980937306 countsByYear W29809373062021 @default.
• W2980937306 countsByYear W29809373062022 @default.
• W2980937306 countsByYear W29809373062023 @default.
• W2980937306 crossrefType "journal-article" @default.
• W2980937306 hasAuthorship W2980937306A5007254355 @default.
• W2980937306 hasAuthorship W2980937306A5008054206 @default.
• W2980937306 hasAuthorship W2980937306A5008204241 @default.
• W2980937306 hasAuthorship W2980937306A5036828560 @default.
• W2980937306 hasAuthorship W2980937306A5038243788 @default.
• W2980937306 hasAuthorship W2980937306A5047631289 @default.
• W2980937306 hasAuthorship W2980937306A5054416214 @default.
• W2980937306 hasAuthorship W2980937306A5055100327 @default.
• W2980937306 hasAuthorship W2980937306A5056554686 @default.
• W2980937306 hasAuthorship W2980937306A5058755419 @default.
• W2980937306 hasAuthorship W2980937306A5059360959 @default.
• W2980937306 hasAuthorship W2980937306A5059772145 @default.
• W2980937306 hasAuthorship W2980937306A5062041233 @default.
• W2980937306 hasAuthorship W2980937306A5062322697 @default.
• W2980937306 hasAuthorship W2980937306A5081151755 @default.
• W2980937306 hasAuthorship W2980937306A5083822738 @default.
• W2980937306 hasAuthorship W2980937306A5087571749 @default.
• W2980937306 hasAuthorship W2980937306A5089625305 @default.
• W2980937306 hasAuthorship W2980937306A5090615083 @default.
• W2980937306 hasBestOaLocation W29809373061 @default.
• W2980937306 hasConcept C126322002 @default.
• W2980937306 hasConcept C143998085 @default.
• W2980937306 hasConcept C194409129 @default.
• W2980937306 hasConcept C197934379 @default.
• W2980937306 hasConcept C2776694085 @default.
• W2980937306 hasConcept C2776755627 @default.
• W2980937306 hasConcept C2777063308 @default.
• W2980937306 hasConcept C2777609679 @default.

• next